Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 5044

Sort by

Sort Order Select

Journal Articles

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Blood (2021) 138 (7): 571–583.

https://doi.org/10.1182/blood.2021010735

Published: 2021

Includes: Supplemental data

Journal Articles

Aspirin and antiplatelet treatments in cancer

Derrick L. Tao, Samuel Tassi Yunga, Craig D. Williams, Owen J. T. McCarty

Blood (2021) 137 (23): 3201–3211.

https://doi.org/10.1182/blood.2019003977

Published: 2021

Journal Articles

A conceptual framework for managing iTTP

Richard J. Benjamin

Blood (2021) 137 (14): 1845–1846.

https://doi.org/10.1182/blood.2021011007

Published: 2021

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

Real-world experience with caplacizumab in the management of acute TTP

Blood (2021) 137 (13): 1731–1740.

https://doi.org/10.1182/blood.2020007599

Published: 2021

Includes: Supplemental data

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

The role of AGK in thrombocytopoiesis and possible therapeutic strategies

Haojie Jiang, Zhuo Yu, Nan Ding, Mina Yang, Lin Zhang, Xuemei Fan, Yuan Zhou, Qiang Zou, Jian Hou, Junke Zheng, Lei Zhang, Yanyan Xu, Junling Liu

Blood (2020) 136 (1): 119–129.

https://doi.org/10.1182/blood.2019003851

Published: 2020

Includes: Supplemental data

Journal Articles

Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report

Lauri M. Burroughs, Aleksandra Petrovic, Ruta Brazauskas, Xuerong Liu, Linda M. Griffith, Hans D. Ochs, Jack J. Bleesing, Stephanie Edwards, Christopher C. Dvorak, Sonali Chaudhury, Susan E. Prockop, Ralph Quinones, Frederick D. Goldman, Troy C. Quigg, Shanmuganathan Chandrakasan, Angela R. Smith, Suhag Parikh, Blachy J. Dávila Saldaña, Monica S. Thakar, Rachel Phelan, Shalini Shenoy, Lisa R. Forbes, Caridad Martinez, Deepak Chellapandian, Evan Shereck, Holly K. Miller, Neena Kapoor, Jessie L. Barnum, Hey Chong, David C. Shyr, Karin Chen, Rolla Abu-Arja, Ami J. Shah, Katja G. Weinacht, Theodore B. Moore, Avni Joshi, Kenneth B. DeSantes, Alfred P. Gillio, Geoffrey D. E. Cuvelier, Michael D. Keller, Jacob Rozmus, Troy Torgerson, Michael A. Pulsipher, Elie Haddad, Kathleen E. Sullivan, Brent R. Logan, Donald B. Kohn, Jennifer M. Puck, Luigi D. Notarangelo, Sung-Yun Pai, David J. Rawlings, Morton J. Cowan

Blood (2020) 135 (23): 2094–2105.

https://doi.org/10.1182/blood.2019002939

Published: 2020

Journal Articles

Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice

Zoltan Nagy, Jun Mori, Vanesa-Sindi Ivanova, Alexandra Mazharian, Yotis A. Senis

Blood (2020) 135 (18): 1574–1587.

https://doi.org/10.1182/blood.2019002848

Published: 2020

Includes: Supplemental data

Journal Articles

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

Régis Peffault de Latour, Sylvie Chevret, Anna Lisa Ruggeri, Felipe Suarez, Laetitia Souchet, David Michonneau, Flore Sicre de Fontbrune, Tereza Coman, Nathalie Dhedin, Marie Thérèse Rubio, Stéphanie Nguyen, Mohamad Mohty, Gérard Socié

Blood (2020) 135 (3): 227–229.

https://doi.org/10.1182/blood.2019000358

Published: 2020

Includes: Supplemental data

Journal Articles

Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death

Susanna F. Fustolo-Gunnink, Karin Fijnvandraat, David van Klaveren, Simon J. Stanworth, Anna Curley, Wes Onland, Ewout W. Steyerberg, Ellen de Kort, Esther J. d’Haens, Christian V. Hulzebos, Elise J. Huisman, Willem P. de Boode, Enrico Lopriore, Johanna G. van der Bom

Blood (2019) 134 (26): 2354–2360.

https://doi.org/10.1182/blood.2019000899

Published: 2019

Includes: Supplemental data

Journal Articles

Platelet lamellipodium formation is not required for thrombus formation and stability

Yvonne Schurr, Andreas Sperr, Julia Volz, Sarah Beck, Lucy Reil, Charly Kusch, Patrick Eiring, Sheila Bryson, Markus Sauer, Bernhard Nieswandt, Laura Machesky, Markus Bender

Blood (2019) 134 (25): 2318–2329.

https://doi.org/10.1182/blood.2019002105

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders

Blood (2019) 134 (23): 2082–2091.

https://doi.org/10.1182/blood.2018891192

Published: 2019

Includes: Supplemental data

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Yihong Guan, PhD, Bhumika J. Patel, MD, Metis Hasipek, PhD, Dale Grabowski, BS, Hassan Awada, MD, Cassandra M Kerr, MS, Valeria Visconte, PhD, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 453.

https://doi.org/10.1182/blood-2019-131525

Published: 2019

Journal Articles

The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning

Blood (2019) 134 (Supplement_1): 635.

https://doi.org/10.1182/blood-2019-126128

Published: 2019

Journal Articles

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Claire N Harrison, Professor, Jacqueline S Garcia, MD, Ruben A Mesa, MD, Tim CP Somervaille, MD PhD, Rami S. Komrokji, MD, Naveen Pemmaraju, MD, Catriona Jamieson, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, James M. Foran, MD, Casey L. O'Connell, MD, Leanne Holes, BS, MBA,, Jia Jia, PhD MBA, Jason Harb, PhD, Jessica Hutti, PhD, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 671.

https://doi.org/10.1182/blood-2019-130158

Published: 2019

Journal Articles

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Blood (2019) 134 (Supplement_1): 648.

https://doi.org/10.1182/blood-2019-125053

Published: 2019

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

https://doi.org/10.1182/blood-2019-130362

Published: 2019

NARROW

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Aspirin and antiplatelet treatments in cancer

A conceptual framework for managing iTTP

Redefining outcomes in immune TTP: an international working group consensus report

Real-world experience with caplacizumab in the management of acute TTP

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

The role of AGK in thrombocytopoiesis and possible therapeutic strategies

Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report

Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death

Platelet lamellipodium formation is not required for thrombus formation and stability

Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only